Exchange: NASDAQ·Updated 07:51 PM EST
CGTX logo

CGTX Cognition Therapeutics Inc

$0.5822
$0.0184
(3.06%)
Today
Closed $0.5822
$0.0022
(0.38%)
After Hours
Reported EarningsNov 5
Mkt Cap$55.37M
Vol665,417.00

About CGTX

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
62

Bullish Sentiment

How do you feel about CGTX?

Biopharma2021
$CGTX can’t believe 2 phase 3 blockbuster medication assets with heavy endorsement from fda and heavy nih funding and endorsement and waiting for 504 pts start trial results next year and stock price is sitting at 66 cents . I have never seen this type of bargain in my biopharma investment history . Happy friday to cgtx longs .
17
Beach_Bums
$CGTX For those who are holding long like myself, what are your predictions for 2027/2028 and why? Of course I would love this to hit $100+ but realistically as of now I would love to see this pump to $35-45+ based on: 1. FDA alignment on Phase 3 — Biggest immediate positive 2. Encouraging Phase 2 results 3. New patent protection through 2045 4. Major unmet medical need 5. Partnership or buyout potential 6. Cash runway into late 2027 7. Potential beyond one disease
14
agarfield
$CGTX I did not realize that that meeting already gave them everything they needed to remove the trial ambiguity, so they don't have to wait until Nov to pursue funding options. So they can go to NIH and make a pitch now; I think they need around 40-60 mil which should be more than feasible to attain (I think their history with the NIH should help move things along a little bit quicker). If they go that route, the funding would line up right at the time they said the trial would start in 2027. Taking a while, but pieces lining up. For a micro-bio, great progress.
13
GibsonFlyingV
$CGTX just enjoying the dip and buying more. To everyone blaming Lisa; 1. Other potential treatments have failed. 2. The NIH backed this. 3. Lisa owns 1,754,702 shares. Her spouse owns more than 38,000 shares. 4. The science hasn’t changed.
12
nostic
$CGTX another anti-amyloid AD trial fails. Probably about $160M down the drain. Well, not down the drain exactly. It seemed to do a fabulous job of showing that clearing amyloid plaques doesn't lead to better outcomes. Good grief, can we please get some recognition of how Z takes a totally different approach and has 9-month trial designs ready to go!
12
alcat1973
$CGTX News of a grant, private funding or even fda fast track are all feasible here. Don't let the drop in share price or delisting notification distract your thinking. There is nothing ou currently available to treat this large segment of patients in desperate need of a solution. You will thank me next year.
10
TwizzlersForSale
$CGTX Buried a loved one today, lost the fight against DLB & Alzheimers. Would’ve given the world to slow it down. Feeling overwhelmed 😔😔😔
10
nostic
$CGTX from a neuroscientist who I follow that has been advocating for thinking beyond amyloid plaques for many years...
1
6
agarfield
$CGTX Leqembi posted their 5 year data showing, "Five Years of Continuous Lecanemab Treatment Extended the Time Patients Remained in the Early Stages of AD Compared with the Natural History of AD, with Benefit Continuing to Accrue Over Time" CGTX provides that maintenance benefit at a much cheaper cost and simplicity. Leqembi and Kisunla can act as an immediate cleanup, and then migrate the patient to Z for maintenance. Combo therapy will be the way to go here. Very confident on positive results post START and 3 big-name players that will have a lot of interest in securing that.
1
6
agarfield
$CGTX Eli Lilly's DLB/ALZ asset failed ALZ phase 2 trials and is being dropped. In my opinion, they are frontrunners for a potential acquisition here as their asset in the same area has failed, Kisunla patent usage can be expanded with combination therapy with vitamin Z, and Lilly is sitting on tons of cash and upcoming patent cliffs. The decision to include Kisunla and Leqembi patients in START was good as this increases likelihood for a bidding war between multiple parties. I was hoping for something sooner, but maybe with Lilly recent failure, we might get some earlier news. Few players in the DLB space.
9
Shawshank_book_keeper
$CGTX definition of insanity according to Einstein is doing the same thing over and over expecting different results… let me take a guess.. acumen pharma failed their phase 2 AD trial with another Ig conjugate?? Can’t be as crazy as the failed trial by Novo Nordisk using semaglutide for early onset Alzheimer’s 🤣
8
nostic
$CGTX AriBio and Cognito had mixed trial results, which actually look to help the outlook for CGTX and its START trial (see image). Priavoid reads out a Phase 2b study for anti-oligomers tomorrow morning, which will also have implications for zervimesine. It was also fascinating to learn that AriBio got a $4.7B partnership deal from a Chinese pharma company (Fosun). Obviously that is mostly backloaded and milestones, but still... it pays for trials. After all that and all this NIH funding, you're telling me they can't find $100M for the DLB psychosis trial? C'mon!
7
Shawshank_book_keeper
$CGTX reduced amount of grant money going towards aging and dementia.. going to be alot harder for bios in this space but cognition already had $200 million in funding. Now on to phase 3 😂
4
TwizzlersForSale
$CGTX In all honesty, get FDA clearance, and put the pills up on a private e-commerce site for sale like HIMS with their pills for hair loss and viagra. We’ll buy private out of pocket for our loved ones, thanks..👍🏻
7
shmewdog
$CGTX RIP Patrick Stewart. This disease has officially claimed one of the world's most beloved and iconic entertainers. As terrible as his passing is, may it bring more attention to the suffering of many people will this illness. May it shine light on the brilliant work this company has done to prevent these conditions and prolong the healthy lives of those afflicted.
7
Shawshank_book_keeper
$CGTX PRI 002 is a D peptide that tries to disentangle the oligomer protein.. another insane approach… as if the many failures of an antibody attacking a protein molecule weren’t enough.. now we are attempting to use a protein molecular to attack a larger protein molecule 😂… if only there was a way to directly bind a receptor that displaces the protein
6
shmewdog
$CGTX I think that the price action today is a result of broader market sentiment than anything particular to the company. I agree that its frustrating that the FDA doesn't seem to know what it wants 8n regards to the trials, but the reduced number of participants should keep the costs down. Nothing has fundamentally changed about the efficacy of the drug. I am not averaging down yet as I anticipate more pain, but I am never selling. I will ride this until we go to zero but it will never come to that
6
Guptasulo
$CGTX 1. Share price versus clinical progress. A biotech company's share price does not always reflect its clinical progress. 2. DLB Phase 3 is next. Single pivotal trial with fewer than half the originally contemplated 750 patients, and nine months of treatment. Re-engaging experienced SHIMMER investigators and sites could potentially reduce costs. 3. START and the partnership opportunity. A potential AD licensing agreement involving upfront payments, milestones and royalties could finance DLB Phase 3. 4. CGTX raised only ~$50K through its ATM in Q3, suggesting restraint vs dilution. 5. Reverse split (RS) concerns. CGTX has until May 3, 2027, to regain Nasdaq's $1 minimum bid compliance, with a possible extension. (I personally see no issues here) 6. Dr. Susan Catalano(Scientist), original co-founder of CGTX with ownership stake and over two decades of scientific research before she discovered CT1812. Clinical success, takes effort, risk and pure dedication. Patience matters.
5
PickAndSee
$CGTX "Having just concluded our discussions with the FDA and having just received their minutes, we're now evaluating our options with investors, bankers, and strategics to secure sufficient funding to conduct the study. In parallel, we're evaluating vendors for CRO partners, as well as the look at initially clinical sites for the trial. Our goal remains to initiate this study in mid-2027." - Lisa Can't think of a more deserving DLB drug for non-dilutive funding - hopefully topline data isn't too late
5
Biopharma2021
$CGTX Just checked on dilution tracker no Atm dilution do not listen soft bashers . last Atm dilution was done dec 2025 .
5

Advertisement|Remove ads.